Medtronic plc reported fiscal third‑quarter 2026 results that marked the company’s highest organic revenue growth in ten quarters, with revenue rising 6.0% year‑over‑year to $9.017 billion. The increase was driven largely by a 13.8% jump in the cardiovascular portfolio and an 80% surge in cardiac ablation solutions, powered by the company’s pulsed‑field ablation technology.
Non‑GAAP earnings per share reached $1.36, beating the consensus estimate of $1.33–$1.35 by $0.01–$0.03. The beat reflects disciplined cost management and the high‑margin mix of cardiovascular products, which offset modest pricing pressure in other segments. GAAP diluted EPS of $1.07 also exceeded expectations, underscoring the company’s ability to generate cash flow across its business lines.
Operating performance improved, with a non‑GAAP operating margin of 24.1% and a GAAP margin of 16.2%. The margin expansion relative to the prior year’s 26.2% non‑GAAP margin is attributable to a shift toward higher‑margin cardiovascular and neuromodulation products, even as the company invested in new technologies and faced moderate cost inflation.
Medtronic reiterated its full‑year 2026 guidance, maintaining an organic revenue growth target of approximately 5.5% and a diluted non‑GAAP EPS range of $5.62 to $5.66. The company also confirmed that a $185 million tariff impact is already factored into the outlook, signaling confidence that the company can navigate ongoing trade‑related headwinds.
Management highlighted the company’s strategic pivot away from its lower‑growth diabetes business toward high‑margin cardiovascular and neuromodulation segments. CEO Geoff Martha said, "Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio." He added, "By unlocking new markets and investing in high‑growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long‑term growth. It's an exciting time for Medtronic." CFO Thierry Piéton noted, "This quarter, we again delivered accelerated growth while investing decisively in our future."
The results reinforce Medtronic’s focus on high‑growth, high‑margin opportunities, particularly pulsed‑field ablation, renal denervation, neuromodulation, and robotic‑assisted surgery. While the company’s diabetes business remains a smaller contributor, the planned separation of that unit by the end of 2026 is expected to further sharpen the company’s growth trajectory.
Investors remain cautious, focusing on valuation and the tariff impact, but the strong earnings beat and reaffirmed guidance suggest that Medtronic’s execution remains robust and its strategic priorities are on track.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.